Results 51 to 60 of about 14,564 (189)

Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Vascular normalization, one promising anti‐angiogenic strategy, has the potential to enhance vascular perfusion and elevate the infiltration of immune cells into tumors by rectifying aberrant tumor blood vessels. This results in the enhancement of immunotherapy.
Yu Tang, Yuyan Ding, LiPing Wang, Yujiao Yang, Youwei Han, Peng Zhou, Huiheng Qu, Kaiyuan Deng, Jiazeng Xia   +8 more
wiley   +1 more source

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

BMC Ophthalmology
Background To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Nozomu Hashiya, Ichiro Maruko, Yuri Miyaguchi, Ruka Maruko, Taiji Hasegawa, Tomohiro Iida   +5 more
doaj   +1 more source

Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis

Frontiers in Pharmacology
BackgroundThis study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).MethodsWe ...
Yating Zhou, Zongyue Zhan, Zixun Wang, Chen Liu   +3 more
doaj   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition

Respirology Case Reports, Volume 14, Issue 5, May 2026.
We report a case of multifocal pyogenic granuloma that developed during ramucirumab therapy but did not recur after switching to bevacizumab. ABSTRACT Pyogenic granuloma is a benign vascular lesion that may bleed repeatedly and impair daily activities.
Akina Nigi, Keisuke Iwamoto, Hidetoshi Itani, Shigeto Kondou   +3 more
wiley   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy: Methods & Clinical Development
Ixoberogene soroparvovec (ixo-vec), formerly ADVM-022, is an adeno-associated virus (AAV) gene therapy using the AAV.7m8 capsid for intravitreal delivery (IVT) to transduce retinal tissue and produce sustained intraocular aflibercept for treating ...
Kris Poulsen, Kelly Hanna, Julio Nieves, Ngoc Nguyen, Pallavi Sharma, Ruslan Grishanin, Romu Corbau, Szilárd Kiss   +7 more
doaj   +1 more source

Aflibercept in the Treatment of Metastatic Colorectal Cancer

, 2012
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment.
Wang, Tzu-Fei, Tzu-Fei Wang, Albert Craig Lockhart, Lockhart, Albert Craig   +3 more
core   +1 more source

Viability of Primary Human Pigment Epithelium Cells and Muller-Glia Cells after Intravitreal Ziv-Aflibercept and Aflibercept [PDF]

, 2016
Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing ...
Haritoglou, Christos, Wolf, Armin, Eibl, Kirsten, Rodrigues, Eduardo Buchele, Farah, Michel Eid [UNIFESP], de Andrade, Gabriel Costa [UNIFESP], Costa de Andrade, G., Wertheimer, Christian, Eibl, Kirsten H., Haritoglou, Christos [UNIFESP], Farah, Michel Eid, Rodrigues, Eduardo Buchele [UNIFESP], Kampik, Anselm   +12 more
core   +1 more source

Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). [PDF]

, 2020
PURPOSE To investigate differences in the development of macular atrophy (MA) over 24 months between treat-and-extend (T&E) ranibizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD).
Gillies, MC, Wolf, S, Gillies, Mark C, Pecheur, Francois L, Munk, Marion, Arnold, JJ, Arnold, Jennifer J, McAllister, IL, Hunyor, Alex P, McAllister, Ian L, Guymer, RH, Guymer, Robyn H, Hunyor, AP, Pecheur, FL, Munk, MR, Wolf, Sebastian   +15 more
core   +1 more source